scanX
Sun Pharmaceutical
1,687.80
+0.40(+0.02%)
Market Cap₹4,04,959.76 Cr
PE Ratio35.29
IndustryHealthcare
Company Performance:
1D+0.02%
1M-0.72%
6M-6.93%
1Y+11.72%
5Y+247.43%
View Company Insightsright
Latest news about Sun Pharmaceutical
FDA Inspection at Sun Pharma's Halol Plant Yields 8 Observations, Facility Remains Under Import Alert 22 hours ago Yesterday
Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat has received a Form 483 from the US FDA following a GMP inspection from June 2-13. The form outlines eight observations, indicating potential GMP compliance issues. This development is significant as the facility is already under import alert due to a previous warning letter. Sun Pharma is expected to review and address these observations to ensure compliance with FDA standards. The Halol facility is crucial for Sun Pharma's US market supply, making resolution of these regulatory issues essential for the company's operations.
Sun Pharma Announces Leadership Transition: Kirti Ganorkar Named New Managing Director, Dilip Shanghvi to Become Executive Chairman 1 day ago
Sun Pharma's SCD-044 Phase 2 Trial Falls Short of Primary Endpoint Jun 04, 2025
Sun Pharma Discontinues SCD-044 Drug After Failed Trials in Psoriasis and Atopic Dermatitis Jun 03, 2025
Sun Pharma Projects Growth on New Launches Amid Profitability Challenges Jun 02, 2025
More news about Sun Pharmaceutical
01Jun 25
Sun Pharma Unveils $100 Million Investment Plan for Specialty Products in FY26
Sun Pharmaceutical Industries plans to invest $100 million in FY26 to commercialize new specialty products, focusing on Unloxcyt and Leqselvi. The company aims for mid-to-high single-digit consolidated topline growth and will allocate 6-8% of sales to R&D. Sun Pharma is acquiring Checkpoint Therapeutics and seeking a partner for MM-II development. These strategic moves are aimed at strengthening its product pipeline and market position in the specialty pharmaceutical sector.
30May 25
Sun Pharma Completes Acquisition of Checkpoint Therapeutics
Sun Pharmaceutical Industries Ltd has successfully acquired Checkpoint Therapeutics, a company focused on developing cancer treatments. This strategic move is expected to expand Sun Pharma's oncology portfolio, enhance its R&D capabilities, and strengthen its position in the global pharmaceutical market. The acquisition could lead to synergies in research, development, and commercialization of cancer treatments. Specific financial details of the deal were not disclosed.
24May 25
Sun Pharma Sets Sights on Mid-to-High Single-Digit Revenue Growth for FY26
Sun Pharmaceutical Industries Ltd has announced its revenue growth target for fiscal year 2026, aiming for a mid-to-high single-digit increase. This projection factors in potential regulatory uncertainties in the crucial U.S. market. The company's strategy suggests a focus on sustainable expansion through diversification, innovation, market expansion, and operational efficiency. This cautious yet optimistic outlook reflects Sun Pharma's pragmatic approach to growth amid complex global pharmaceutical regulations.
23May 25
Sun Pharma Invests $25 Million in Pharmazz Inc, Increasing Stake to 22.7%
Sun Pharmaceutical Industries Ltd has agreed to invest up to $25 million in Pharmazz Inc, increasing its stake to 22.7%. The investment supports the development of two advanced drug candidates for stroke and shock. Sun Pharma gains options for licensing rights in certain markets, aligning with its strategy to expand its portfolio and market presence in specialty areas.
23May 25
Sun Pharma Q4 Profit Dips, Revenue Rises; Announces Dividend
Sun Pharmaceutical Industries Ltd reported mixed Q4 results. Net profit decreased to ₹21.50 billion from ₹26.50 billion year-over-year, falling short of market expectations. Revenue increased to ₹129.59 billion from ₹119.80 billion. The company reported an exceptional item of ₹3.62 billion and improved profit before tax of ₹36.20 billion. The board recommended a final dividend of ₹5.50 per equity share.
21May 25
Sun Pharma Q4 Preview: Revenue Growth Expected at 12.9%, Driven by gRevlimid Sales
Sun Pharmaceutical Industries Ltd is set to announce its Q4 results on Thursday. Analysts project a 12.9% YoY revenue increase to Rs 13,254.38 crore, driven by gRevlimid sales. Net profit is expected to rise 5.24% YoY to Rs 2,793.94 crore. US market revenues are anticipated to grow 10% YoY, with healthy growth in India and emerging markets. Investors will focus on R&D guidance, acquisition updates, and plant resolution progress.
20May 25
Sun Pharma Acquires Checkpoint Therapeutics for $616 Million, Bolstering Dermatology-Oncology Portfolio
Sun Pharmaceutical Industries has acquired Checkpoint Therapeutics for $616 million, including a $355 million upfront payment, $60 million contingent payment, and additional royalties. The acquisition, aimed at strengthening Sun Pharma's dermatology-oncology market position, brings key asset Unloxcyt to their portfolio. Macquarie views the deal as value accretive and has raised Sun Pharma's target price to Rs 2,135.00.
19May 25
Sun Pharma's BLU-U Device Upgrade Receives FDA Approval for Skin Treatment
Sun Pharmaceutical Industries has received FDA approval for an upgraded version of its BLU-U Blue Light Photodynamic Therapy device. The new model transitions from fluorescent tubes to LED technology, offering improved efficiency and usability in treating actinic keratosis, a pre-cancerous skin condition. This approval marks a significant advancement in Sun Pharma's medical device portfolio and reinforces its position in dermatological treatments.
16May 25
Sun Pharma's New Photodynamic Therapy Device Receives FDA Approval
Sun Pharmaceutical Industries Ltd. has received FDA approval for its next-generation Blu-U® Blue Light Photodynamic Therapy Illuminator, designed to treat actinic keratosis, a pre-cancerous skin condition. This approval enhances Sun Pharma's dermatology portfolio and reinforces its position in the global dermatology market. The device uses photodynamic therapy for treating pre-cancerous skin lesions, potentially improving patient care and treatment outcomes.
06May 25
Sun Pharma Appoints Jayashree Satagopan as New Chief Financial Officer
Sun Pharmaceutical Industries Ltd. has named Jayashree Satagopan as its new Chief Financial Officer. Satagopan will oversee financial operations, develop strategies, ensure regulatory compliance, and support growth initiatives for the leading Indian pharmaceutical company. This appointment marks a significant change in Sun Pharma's top management, potentially influencing the company's financial direction and performance in the competitive pharmaceutical industry.
24Apr 25
Sun Pharma and Moebius Medical Unveil Promising Results for Novel Osteoarthritis Treatment
Sun Pharmaceutical Industries and Moebius Medical have published two groundbreaking articles in Osteoarthritis and Cartilage journal, showcasing the potential of their novel osteoarthritis treatment, MM-II. A Phase 2b trial demonstrated that a single MM-II injection provided pain relief for up to 26 weeks in knee osteoarthritis patients. The treatment's unique mechanism forms a lubricative layer over cartilage surfaces, potentially reducing friction and slowing cartilage degeneration. MM-II has received Fast Track Designation from the FDA, and new data will be presented at OARSI 2025. The global market for knee osteoarthritis pain relief products is estimated at $2 billion with a 6.5% CAGR.
22Apr 25
Sun Pharma Shares Witness Significant Block Trade on NSE
Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE), involving 90,708 shares valued at Rs. 15.81 crores. The trade was executed at Rs. 1,742.80 per share, representing a substantial portion of the day's trading volume. This transaction highlights ongoing interest in Sun Pharma's stock among large investors.
16Apr 25
Sun Pharma Sees Significant Block Trade on NSE
Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 125,345 shares traded at Rs. 1,688.90 per share, totaling Rs. 21.17 crores. This large-scale trade has drawn attention from market observers and investors, potentially influencing market sentiment and stock price movements.
11Apr 25
Sun Pharma Wins Court Ruling, Clears Path for LEQSELVI Launch in U.S.
Sun Pharmaceutical Industries Ltd has secured a favorable ruling from the U.S. Court of Appeals, vacating a preliminary injunction that previously blocked the launch of its autoimmune disorder drug, LEQSELVI (deuruxolitinib), in the United States. The drug targets patchy hair loss. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI. The company will announce its launch plans for the drug in due course.
10Apr 25
Sun Pharma Wins US Court Appeal, Clears Path for LEQSELVI Launch
Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction, allowing Sun Pharma to proceed with the launch of LEQSELVI™ (deuruxolitinib), its autoimmune-related hair loss drug. This decision, made on April 9, 2025, overturns a previous ruling by the U.S. District Court for the District of New Jersey. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI™ and will announce its launch plans in due course.
10Apr 25
Sun Pharma's Leqselvi Gets Green Light as US Court Vacates Injunction
Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction on April 9, 2025, allowing Sun Pharma to proceed with the launch of Leqselvi (deuruxolitinib), a treatment for severe alopecia areata. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching the medication and will announce its launch plans soon.
07Apr 25
Sun Pharma Launches Fexuclue: A Novel Treatment for Erosive Esophagitis in India
Sun Pharmaceutical Industries Limited has introduced Fexuclue® (Fexuprazan), a novel potassium-competitive acid blocker (P-CAB) for treating Erosive Esophagitis in adults. The medication offers fast-acting, flexible dosing and long-lasting effects. A Phase 3 study showed over 95% efficacy in healing Erosive Esophagitis by 8 weeks. This launch addresses an unmet need in India, where GERD prevalence ranges from 7.60% to 30.00%. The product results from a collaboration with Daewoong Pharmaceutical Co Ltd.
01Apr 25
Sun Pharma Advanced Research Submits IND Application for Cancer Drug SBO-154 to FDA
Sun Pharma Advanced Research Company (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154, a novel compound targeting advanced solid tumors, to the U.S. FDA. This submission paves the way for global Phase 1 clinical trials, potentially leading to new treatment options for cancer patients. The move underscores SPARC's commitment to oncology innovation and could strengthen its position in cancer drug development.
18Mar 25
Sun Pharma Completes CAD 4.5 Million Acquisition of Antibe Therapeutics
Sun Pharmaceutical Industries Limited has finalized its acquisition of Canadian firm Antibe Therapeutics Inc. through its subsidiary TARO Pharmaceuticals Inc. The deal, valued at CAD 4.5 million (approx. ₹27.45 crore), was completed on March 18, 2025. This strategic move aims to expand Sun Pharma's product portfolio and strengthen its presence in the North American market.
11Mar 25
Sun Pharma Acquires Checkpoint Therapeutics in $450 Million Deal to Boost Specialty Business
Sun Pharmaceutical Industries Ltd has agreed to acquire Checkpoint Therapeutics, Inc. for approximately $450 million. The deal, set to close in the second half of 2025, involves a cash payment of $4.10 per share plus potential contingent value rights of up to $0.70 per share. This acquisition aims to strengthen Sun Pharma's specialty business, particularly in dermatology, ophthalmology, and oncology. The key asset is cosibelimab, an anti-PD-L1 antibody in development for treating advanced cutaneous squamous cell carcinoma. The acquisition is expected to be earnings accretive within the first full year after closing.
10Mar 25
Sun Pharma to Acquire Checkpoint Therapeutics for $355 Million, Bolstering Onco-Dermatology Portfolio
Sun Pharmaceutical Industries Ltd is set to acquire Nasdaq-listed Checkpoint Therapeutics, Inc. for up to $355 million. The deal includes an upfront payment of $4.10 per share and a potential additional $0.70 per share contingent on European regulatory approval for Cosibelimab. This acquisition will strengthen Sun Pharma's global specialty product portfolio, particularly in onco-dermatology. The key asset is UNLOXCYT™, an FDA-approved treatment for advanced cutaneous squamous cell carcinoma (cSCC). The deal is expected to close in the second quarter of 2025, subject to regulatory and stockholder approvals.
Sun Pharmaceutical
1,687.80
+0.40
(+0.02%)
1 Year Returns:+11.72%
Industry Peers
Sun Pharmaceutical
1,687.80
(+0.02%)
Divis Laboratories
6,667.00
(-0.86%)
Cipla
1,505.20
(+0.16%)
Dr Reddys Laboratories
1,362.50
(-0.01%)
Torrent Pharmaceuticals
3,252.50
(-0.19%)
Mankind Pharma
2,381.30
(-0.36%)
Zydus Life Science
974.95
(-0.39%)
Lupin
1,999.60
(-1.17%)
Abbott
31,515.00
(-0.19%)
Aurobindo Pharma
1,150.20
(-0.43%)

Get More Market Insights with

insight.name

Heatmap

insight.name

FII/DII

insight.name

Company Filings

insight.name

MF Holdings

insight.name

Bulk/Block Deals

insight.name

Signals

insight.name

MTF Insights

insight.name

F&O Ban - MWPL

insight.name

Top Deliveries

insight.name

Market Valuation

raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Fundamental Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104